To adapt Veroplex cell platform for rapid response to viral threats for Department of Defense
Contract Pharma Staff04.24.20
The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices
, a biologics contract development and manufacturing organization (CDMO), to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases.
“The Veroplex platform has the possibility to allow rapid vaccine development for many potential emerging viral infectious diseases,” said Peter Khoury, president and chief executive officer, Ology Bioservices. “There is solid evidence that this Vero cell line, when combined with recent innovations in vaccine manufacturing technology, may be valuable in quickly manufacturing vaccines and other biologics in a very small footprint.”